Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Genetic modulation of oral anticoagulation with warfarin.

Margaglione M, Colaizzo D, D'Andrea G, Brancaccio V, Ciampa A, Grandone E, Di Minno G.

Thromb Haemost. 2000 Nov;84(5):775-8.

PMID:
11127854
2.

Reply to rebuttal: Gene variants of the cytochrome P450 CYP2C9 affect oral anticoagulation with warfarin.

Margaglione M, Brancaccio V, Ciampa A, Di Minno G.

Thromb Haemost. 2001 Sep;86(3):938. No abstract available.

PMID:
11583336
3.

Interindividual variability in sensitivity to warfarin--Nature or nurture?

Loebstein R, Yonath H, Peleg D, Almog S, Rotenberg M, Lubetsky A, Roitelman J, Harats D, Halkin H, Ezra D.

Clin Pharmacol Ther. 2001 Aug;70(2):159-64.

PMID:
11503010
5.

[Warfarin in the treatment of antiphospholipid syndrome].

Reshetniak TM, Kondrat'eva LV, Patrusheva NL, Patrushev LI.

Ter Arkh. 2007;79(5):47-54. Russian.

PMID:
17672075
6.

Polymorphisms in factor II and factor VII genes modulate oral anticoagulation with warfarin.

D'Ambrosio RL, D'Andrea G, Cappucci F, Chetta M, Di Perna P, Brancaccio V, Grandone E, Margaglione M.

Haematologica. 2004 Dec;89(12):1510-6.

7.

Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy.

Higashi MK, Veenstra DL, Kondo LM, Wittkowsky AK, Srinouanprachanh SL, Farin FM, Rettie AE.

JAMA. 2002 Apr 3;287(13):1690-8.

PMID:
11926893
8.

Determination of bleeding risk using genetic markers in patients taking phenprocoumon.

Hummers-Pradier E, Hess S, Adham IM, Papke T, Pieske B, Kochen MM.

Eur J Clin Pharmacol. 2003 Jul;59(3):213-9. Epub 2003 May 1.

PMID:
12728288
9.

The frequency and effects of cytochrome P450 (CYP) 2C9 polymorphisms in patients receiving warfarin.

Tabrizi AR, Zehnbauer BA, Borecki IB, McGrath SD, Buchman TG, Freeman BD.

J Am Coll Surg. 2002 Mar;194(3):267-73.

PMID:
11893129
10.

Genetic association between sensitivity to warfarin and expression of CYP2C9*3.

Steward DJ, Haining RL, Henne KR, Davis G, Rushmore TH, Trager WF, Rettie AE.

Pharmacogenetics. 1997 Oct;7(5):361-7.

PMID:
9352571
11.
12.

Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy.

Furuya H, Fernandez-Salguero P, Gregory W, Taber H, Steward A, Gonzalez FJ, Idle JR.

Pharmacogenetics. 1995 Dec;5(6):389-92. No abstract available.

PMID:
8747411
13.

CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy.

Peyvandi F, Spreafico M, Siboni SM, Moia M, Mannucci PM.

Clin Pharmacol Ther. 2004 Mar;75(3):198-203.

PMID:
15001971
14.

Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors.

Wadelius M, Sörlin K, Wallerman O, Karlsson J, Yue QY, Magnusson PK, Wadelius C, Melhus H.

Pharmacogenomics J. 2004;4(1):40-8.

PMID:
14676821
15.

Pharmacogenetics of warfarin elimination and its clinical implications.

Takahashi H, Echizen H.

Clin Pharmacokinet. 2001;40(8):587-603. Review.

PMID:
11523725
16.
17.

CYP2C9 polymorphism and warfarin dose requirements.

Daly AK, Day CP, Aithal GP.

Br J Clin Pharmacol. 2002 Apr;53(4):408-9. No abstract available.

18.

Implications of cytochrome P450 2C9 polymorphism on warfarin metabolism and dosing.

Redman AR.

Pharmacotherapy. 2001 Feb;21(2):235-42. Review.

PMID:
11213860
19.

Early acenocoumarol overanticoagulation among cytochrome P450 2C9 poor metabolizers.

Verstuyft C, Morin S, Robert A, Loriot MA, Beaune P, Jaillon P, Becquemont L.

Pharmacogenetics. 2001 Nov;11(8):735-7.

PMID:
11692083
20.

[Significance of cytochrome P450 2C9 genotype for the bleeding complications in patients treated with acenocoumarol].

Márk L, Márki-Zay J, Fodor L, Kondacs A, Paragh G, Katona A.

Orv Hetil. 2005 Apr 17;146(16):739-43. Hungarian.

PMID:
15889670

Supplemental Content

Support Center